Spectrum Pharma (SPPI) Appoints Brittany K. Bradrick to its Board

Spectrum Pharmaceuticals (Nasdaq: SPPI) today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience.

“It’s my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum’s evolution,” stated William Ashton, Chairman of the Board of Spectrum Pharmaceuticals. “As a seasoned executive in M&A and the life sciences sector, Brittany’s experience and leadership will make an immediate impact on our board.”

“I am looking forward to joining Spectrum’s Board at a time when the company has two product candidates that are under FDA review and approaching potential commercialization,” said Ms. Bradrick. “I intend to add value and contribute to the company's mission of developing and delivering innovative medicines for patients with cancer.”

Ms. Bradrick has served as the Chief Financial Officer of Neurelis, Inc. since October 2021. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as Vice President, Strategy & Corporate Development and at Abbott Diabetes Care as the Head of Global Business Development. Prior to these positions, Ms. Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. Ms. Bradrick began her career as a Federal Reserve Bank Examiner. Ms. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.

You May Also Be Interested In

• FDA completes first-cycle review of NRx ketamine ANDA with packaging query
• FDA grants fast track status to Aclaris drug for lichen planus
• GDIT wins $1.3B Army National Guard cybersecurity contract